1.590USDMkt Cap: 95.91M USDP/E: —Last update: 2026-05-21
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, wh…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap95.91M USD
Enterprise Value46.42M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-33.85M USD
Revenue/Share—
Last Price1.590 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees7
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS01438T1060
Valuation
P/E (Trailing)—
P/E (Forward)-7.95
PEG—
EV/EBITDA-1.65
EV/Revenue—
P/S—
P/B2.27
EPS (TTM)-0.45
EPS (Forward)-0.20
52W Range
1.510100% of range1.590
52W High1.590 USD
52W Low1.510 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-76.49%
ROA-46.97%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-33.35M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-20.44%
Net Debt-49.49M USD
Net Debt/EBITDA1.76
Balance Sheet
Debt/Equity0.35
Current Ratio2.72
Quick Ratio2.67
Book Value/Sh0.6990 USD
Cash/Share1.078 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Target (Mean)7.600 USD
Target Range2.000 USD – 13.00 USD
# Analysts5
Ownership
Shares Out.60.32M
Float52.88M
Insiders3.18%
Institutions62.71%
Short Interest
Short Ratio4.4d
Short % Float12.61%
Short % Out.12.21%
Shares Short7.36M
Short (prev mo.)5.49M
Technical
SMA 501.840 (-13.6%)
SMA 2004.334 (-63.3%)
Beta1.15
S&P 52W Chg28.31%
Avg Vol (30d)621.09K
Avg Vol (10d)883.48K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—